RZLT Stock Overview
A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rezolute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.29 |
| 52 Week High | US$6.19 |
| 52 Week Low | US$0.72 |
| Beta | 1.19 |
| 11 Month Change | 9.07% |
| 3 Month Change | 21.89% |
| 1 Year Change | 605.24% |
| 33 Year Change | -2.04% |
| 5 Year Change | -29.65% |
| Change since IPO | -99.20% |
Recent News & Updates
Recent updates
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully
May 22
Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate
Feb 13Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price
Sep 21Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation
Jul 25We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth
Jan 31Rezolute GAAP EPS of -$0.37
Sep 15We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate
May 06Rezolute shares rise on positive topline results from RZ402 eye disease trial
May 04What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?
Jan 12Shareholder Returns
| RZLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.2% | -10.3% | -2.1% |
| 1Y | 605.2% | 13.6% | 29.6% |
Return vs Industry: RZLT exceeded the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: RZLT exceeded the US Market which returned 29.6% over the past year.
Price Volatility
| RZLT volatility | |
|---|---|
| RZLT Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RZLT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RZLT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 18 | Nevan Elam | www.rezolutebio.com |
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema.
Rezolute, Inc. Fundamentals Summary
| RZLT fundamental statistics | |
|---|---|
| Market cap | US$295.86m |
| Earnings (TTM) | -US$69.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.3x
P/E RatioIs RZLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RZLT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$69.31m |
| Earnings | -US$69.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RZLT perform over the long term?
See historical performance and comparison